Literature DB >> 3348141

Effects of long-term treatment with 120 mg of sustained-release isosorbide dinitrate and 60 mg of sustained-release nifedipine on myocardial perfusion.

B Stegaru1, R Loose, H Keller, J Buss, E Wetzel.   

Abstract

Forty patients with coronary artery disease and scintigraphically proven myocardial ischemia were randomized into 2 groups receiving 4 weeks of treatment with either 120 mg of isosorbide dinitrate (ISDN) release or 60 mg of nifedipine release. Control exercise testing and myocardial scintigraphy were continued until anginal pains occurred, and repeated at identical individual workloads at the end of the 4 weeks of drug therapy. Myocardial scintigrams were evaluated by quantitative recording of counts in 60 segments/frame. Twenty patients in the ISDN group (group I) exhibited 47 significantly ischemic areas. The remaining 20 patients (group II), treated with nifedipine, had 50 ischemic areas before therapy. In the ischemic areas in group I, there was a mean difference of 30.9% between counts at rest and during exercise in the pretreatment period, and a difference of 18.1% after therapy (39.0%). In group II, the pretreatment difference was 28.8%, decreasing to 20.6% after therapy (17.8%). Both groups of patients were subsequently subdivided into 3 subsets: (1) significantly improved perfusion, (2) significant worsening, and (3) unchanged myocardial perfusion. Group I had 59.5% of areas with significant improvement and 10.6% of areas with significant worsening. In 29.7% of the areas, the findings were unchanged. Group II had improvement in 40% of areas, of significantly worsened areas in 6%, and unchanged areas in 54%, in both groups myocardial ischemia was reduced by therapy, but ISDN improved myocardial perfusion to a considerably greater extent than did nifedipine.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3348141     DOI: 10.1016/0002-9149(88)90094-x

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

Review 1.  Prognostic value of gated myocardial perfusion SPECT.

Authors:  Leslee J Shaw; Ami E Iskandrian
Journal:  J Nucl Cardiol       Date:  2004 Mar-Apr       Impact factor: 5.952

2.  Patient-centered imaging.

Authors:  E Gordon Depuey; John J Mahmarian; Todd D Miller; Andrew J Einstein; Christopher L Hansen; Thomas A Holly; Edward J Miller; Donna M Polk; L Samuel Wann
Journal:  J Nucl Cardiol       Date:  2012-04       Impact factor: 5.952

3.  Gated myocardial perfusion single photon emission computed tomography in the clinical outcomes utilizing revascularization and aggressive drug evaluation (COURAGE) trial, Veterans Administration Cooperative study no. 424.

Authors:  Leslee J Shaw; Gary V Heller; Paul Casperson; Romalisa Miranda-Peats; Piotr Slomka; John Friedman; Sean W Hayes; Ronald Schwartz; William S Weintraub; David J Maron; Marcin Dada; Spencer King; Koon Teo; Pamela Hartigan; William E Boden; Robert A O'Rourke; Daniel S Berman
Journal:  J Nucl Cardiol       Date:  2006-09       Impact factor: 5.952

Review 4.  Nitrates: why and how should they be used today? Current status of the clinical usefulness of nitroglycerin, isosorbide dinitrate and isosorbide-5-mononitrate.

Authors:  S Silber
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

5.  Residual exercise SPECT ischemia on treatment is a main determinant of outcome in patients with coronary artery disease treated medically at long-term with beta-blockers.

Authors:  Pierre Y Marie; Christelle Mercennier; Nicolas Danchin; Karim Djaballah; Alain Grentzinger; Faïez Zannad; Pierre Olivier; Wassila Djaballah; Gilles Karcher; Jean M Virion; Alain Bertrand
Journal:  J Nucl Cardiol       Date:  2003 Jul-Aug       Impact factor: 5.952

6.  Study of the possible medical and medication explanatory factors of angiographic outcomes in patients with acute ST elevation myocardial infarction undergoing primary percutaneous intervention.

Authors:  Azadeh Eshraghi; Azita Hajhossein Talasaz; Jamshid Salamzadeh; Mostafa Bahremand; Mojtaba Salarifar; Yones Nozari; Yaser Jenab; Mohammad Ali Boroumand; Golnaz Vaseghi; Nazanin Eshraghi
Journal:  Adv Biomed Res       Date:  2014-09-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.